Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Prostatic Neoplasms 2Ovarian Neoplasms 2Lung Neoplasms 2Thyroid Neoplasms 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Rectal Neoplasms 1Pancreatic Neoplasms 1Neoplasms 1Melanoma 1Endometrial Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Oxaliplatin 21Capecitabine 17Fluorouracil 15Irinotecan 11Radiotherapy 10Leucovorin 8Cetuximab 6Bevacizumab 6Gemcitabine 5oblimersen 3fludarabine 3aldesleukin 3Nivolumab 3Erlotinib Hydrochloride 3Cyclophosphamide 3labetuzumab 2dehydroftorafur 2conatumumab 2Tomography, X-Ray Computed 2Receptor Protein-Tyrosine Kinases 2Radiation 2Panitumumab 2Neoadjuvant Therapy 2Magnetic Resonance Imaging 2Interleukin-2 2Gefitinib 2Electrocardiography 2Diphenhydramine 25,10-methylenetetrahydrofolic acid 2tislelizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Rectal Neoplasms × IT-101 × Clear all
NCT02010567 2020-11-03

Neoadjuvant Chemoradiotherapy With CRLX-101 and Capecitabine for Rectal Cancer

UNC Lineberger Comprehensive Cancer Center

Phase 1/2 Terminated
32 enrolled 18 charts
Gastrointestinal

Rectal Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡